PARP inhibition

Compound Palacaparib (AZD9574)

Area under investigation

Advanced solid tumors

Scientific PillarDNA Damage Response

 

Loading......

CERTIS1 trial overview

Tumor

Advanced solid tumors

Trial Identifier

NCT05417594

Phase

I/IIa

Regimen

Palacaparib monotherapy; palacaparib + temozolomide; [11C]AZ14193391 + palacaparib or [11C]AZ14193391 + palacaparib + temozolomide; palacaparib + T-DXd; palacaparib + Dato-DXd

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Study Locator

Explore further trial details, understand eligibility criteria and speak to clinical trial navigators for the CERTIS1 trial via the Breast Cancer Study Locator website.

Target Overview

Poly [ADP-ribose] polymerases (PARPs) are a group of proteins known to be involved in the repair of single-strand breaks in DNA.1

A healthy cell’s DNA undergoes damage every day, with approximately 10,000 spontaneous single-strand breaks that require repair.1

Inhibition of PARP1 with palacaparib (AZD9574) leads to the trapping of PARP1 bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death. In tumor cells that already have compromised DNA repair mechanisms (such as loss of BRCA1 or BRCA2 function, affecting double-strand break repair), inhibition of PARP1 leads to excessive accumulation of DNA damage and may cause death of the cell.1,2

Compound Overview

Palacaparib (AZD9574) is an investigational, next generation CNS penetrant PARP inhibitor. It is designed to selectively inhibit and trap PARP1 as well as specifically penetrate the blood-brain barrier.3,4

 

Mechanism of Action

  • Mechanism of Action
  • Mechanism of Action

References

 

Loading......

CERTIS1 trial overview

Tumor

Advanced solid tumors

Trial Identifier

NCT05417594

Phase

I/IIa

Regimen

Palacaparib monotherapy; palacaparib + temozolomide; [11C]AZ14193391 + palacaparib or [11C]AZ14193391 + palacaparib + temozolomide; palacaparib + T-DXd; palacaparib + Dato-DXd

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Study Locator

Explore further trial details, understand eligibility criteria and speak to clinical trial navigators for the CERTIS1 trial via the Breast Cancer Study Locator website.

Abbreviations

  • BRCA 1/2

    breast cancer susceptibility gene 1/2

  • CNS

    central nervous system

  • DNA

    deoxyribonucleic acid

  • PARP

    poly (ADP-ribose) polymerase

  • PARP1

    poly (ADP-ribose) polymerase 1